Abel Hall, LLC Coherus Bio Sciences, Inc. Transaction History
Abel Hall, LLC
- $157 Billion
- Q4 2024
A detailed history of Abel Hall, LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Abel Hall, LLC holds 14,305 shares of CHRS stock, worth $16,164. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,305Holding current value
$16,164% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
133Shares Held
77.1MCall Options Held
40.7KPut Options Held
50.1K-
Black Rock Inc. New York, NY11.8MShares$13.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$12.8 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$11.8 Million0.3% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$3.43 Million0.18% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.86MShares$3.23 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $87.8M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...